Loading...
XETR
AAQ1
Market cap16mUSD
Jul 22, Last price  
1.58EUR
1D
0.00%
1Q
-13.66%
Jan 2017
-85.69%
Name

Aap Implantate AG

Chart & performance

D1W1MN
XETR:AAQ1 chart
P/E
—
P/S
1.13
EPS
—
Div yield, %
—
Shrs. gr., 5y
31.93%
Rev. gr., 5y
6.03%
Revenues
13m
+2.43%
18,454,00028,006,00031,884,00033,101,00028,440,00029,205,00026,039,00027,672,00030,414,00012,280,00010,486,00010,902,00010,781,00011,739,0009,326,00012,166,00011,516,00011,478,00012,203,00012,500,000
Net income
-3m
L-28.37%
1,540,0001,511,000-5,234,0001,938,00051,000395,0002,410,000-2,454,000-456,000-5,291,000-9,269,000-9,271,000-7,666,000-19,439,000-8,937,000-2,522,000-2,564,000-5,125,000-3,630,000-2,600,000
CFO
-1m
L+27.58%
1,729,000-299,000544,0004,761,0002,654,0003,213,0007,088,0003,547,000-2,945,000-2,265,000-7,203,000-5,428,000-5,919,000-5,767,000-3,675,000-2,470,000-1,893,000-2,992,000-1,124,000-1,434,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Operating as a medical technology firm, aap Implantate AG specializes in the development, manufacturing, and commercialization of orthopedic trauma devices. The company's market presence spans Germany, the United States, and various international regions. Its primary offerings feature LOQTEQ, an advanced anatomical plating system crucial for fracture treatment, in addition to a diverse selection of cannulated screws, conventional plates, and standard screws. Products are distributed under the 'aap' brand, reaching customers directly, including hospitals, purchasing syndicates, and hospital groups, as well as indirectly via its network of distributors. aap Implantate AG was founded in 1990 and maintains its corporate headquarters in Berlin, Germany.
URL
https://www.aap.de/
IPO date
May 10, 1999
Employees
111
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT